Results 271 to 280 of about 401,950 (315)
Some of the next articles are maybe not open access.
EGFR and anti-EGFR nanobodies: review and update
Journal of Drug Targeting, 2020Targeted therapy is one of the favourable methods used in cancer treatment. Several recombinant proteins and small-molecules used for this aim include monoclonal antibodies, antibody fragments and peptides. Nanobody (Nb) is a camelid antibody fragment that is very effective in targeted therapy.
Jafar Sharifi +3 more
openaire +2 more sources
Experimental Cell Research, 2011
Anti-Epidermal Growth Factor Receptor (EGFR) therapies have been recently developed for the treatment of multiple cancer types. At the time when they were introduced in clinical practice, there was little knowledge of the molecular bases of tumor sensitivity and resistance to these novel targeted compounds.
Vecchione L +4 more
openaire +3 more sources
Anti-Epidermal Growth Factor Receptor (EGFR) therapies have been recently developed for the treatment of multiple cancer types. At the time when they were introduced in clinical practice, there was little knowledge of the molecular bases of tumor sensitivity and resistance to these novel targeted compounds.
Vecchione L +4 more
openaire +3 more sources
Independent Nurse, 2007
A four part presentation covering the significance of estimated glomerular filtration rate and how to use the test to diagnose chronic kidney disease
Donal O'Donoghue, Ian Wilkinson
openaire +1 more source
A four part presentation covering the significance of estimated glomerular filtration rate and how to use the test to diagnose chronic kidney disease
Donal O'Donoghue, Ian Wilkinson
openaire +1 more source
EGFR blockade activates interferon
Nature Cancer, 2020Dysregulation of innate immune signaling in cancer can be pro-tumorigenic and can promote adaptive resistance to targeted therapies. Type I interferon signaling is now shown to promote survival following inhibition of the kinase EGFR, even in cells that are not ‘addicted’ to EGFR signaling.
Ryohei Yoshida, David A. Barbie
openaire +2 more sources
EGFR mutations and EGFR tyrosine kinase inhibitors
The Lancet Oncology, 2015Valter, Torri +2 more
openaire +2 more sources
2011
Thoracic oncologists traditionally have made treatment decisions based upon tumor histology, distinguishing non-small cell lung cancer (NSCLC) from small cell lung cancer (SCLC). However, recent data has revealed that at least one histological subtype of NSCLC, lung adenocarcinoma comprises multiple molecularly distinct diseases.
Yixuan, Gong, William, Pao
openaire +2 more sources
Thoracic oncologists traditionally have made treatment decisions based upon tumor histology, distinguishing non-small cell lung cancer (NSCLC) from small cell lung cancer (SCLC). However, recent data has revealed that at least one histological subtype of NSCLC, lung adenocarcinoma comprises multiple molecularly distinct diseases.
Yixuan, Gong, William, Pao
openaire +2 more sources
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Nature Reviews Clinical Oncology, 2022Lecia V Sequist, Jessica J Lin
exaly
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Nature Reviews Clinical Oncology, 2021Alex Friedlaender +2 more
exaly